|View printer-friendly version|
Bacterin Announces Preliminary Fourth Quarter 2013 Revenue
Fourth Quarter Revenue in the range of
$8.15 million to $8.28 million, an increase of 4% sequentially, and 1.5% over the same period last year.
Fourth Quarter Biologics Revenue in the range of
$8.02 millionto $8.07 million, up 5.0% sequentially and 4.5% over the same period last year.
Reorganization of sales force initiated
January 1, 2014to drive top-line growth during 2014
The company is expecting total net revenues for the fourth quarter of
2013 to be in the range of
“The return to sequential and year-over-year revenue growth demonstrates
that our transitional strategies are working,” says Bacterin CEO,
The quarterly financial results included in this release are prior to
the completion of review and audit procedures by Bacterin’s external
auditors and are therefore subject to adjustment. Bacterin expects to
provide fourth quarter and full year 2013 financial results during its
fourth quarter 2013 earnings call in
Bacterin's Medical Device division develops and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of the Company’s sales force to achieve expected results, the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company’s secured lending facility; the Company’s ability to manage cash flow; the Company’s ability to obtain shareholder approval of financing transactions; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the Company’s ability to successfully conclude government investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.